The company’s focus on regenerative orthopedics is one of the most rapidly expanding therapeutic sectors in biotechnology. In line with this rapidly expanding market, TissueGene’s product candidates can potentially be used to address a wide range of orthopedic diseases and injuries including osteoarthritis, osteoporosis, non-union bone fractures, spinal disc injuries and nerve damage. TG-C, our lead product candidate, has been developed to specifically address osteoarthritis.
Osteoarthritis is a chronic disease caused by the progressive degeneration of articular cartilage and is characterized by joint pain, stiffness, and limited movement. Currently, it is estimated that osteoarthritis affects over 27 million adults in the US and over 151 million adults worldwide. With the increasing prevalence of osteoarthritis, driven primarily by the increasing aging population and obesity epidemic, a noninvasive treatment such as TG-C that treats not only the symptoms but the causes of osteoarthritis is critical.